Amplia Therapeutics (ASX:ATX) set for AMP945 drug trials
Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of…
Amplia Therapeutics Limited (ASX:ATX)
14.5¢
-0.01 (-6.45%)
MCAP $30.04M
Last trade
11.57am 27/01/2022
20mins delayed
Latest Announcements
24/01/2022 Price SensitivePSATXAmplia Therapeutics Limited
19/01/2022ATXAmplia Therapeutics Limited
13/01/2022 Price SensitivePSATXAmplia Therapeutics Limited
23/12/2021ATXAmplia Therapeutics Limited
312
MCap
22/12/2021ATXAmplia Therapeutics Limited
22/12/2021ATXAmplia Therapeutics Limited
22/12/2021ATXAmplia Therapeutics Limited
185
MCap
21/12/2021ATXAmplia Therapeutics Limited
Company Overview
Amplia Therapeutics Limited is an Australia-based clinical-stage drug development company. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
